LEO Pharma Open Innovation

Psoriatic inflammation

Primary human keratinocytes are stimulated with a cytokine cocktail containing TNF-α and IL-17, to induce a psoriasis-relevant inflammatory response, detected as an increase in IL-8 secretion. Your compound is tested for its ability to inhibit this inflammatory response, measured as an inhibition of IL-8 release. Cellular viability is also assessed, as a measure of general compound cytotoxicity.